[hot spot]
Longi Green Energy Technology Co.Ltd(601012) : signed major investment agreement, with the project investment amount of about 19.5 billion yuan
Longi Green Energy Technology Co.Ltd(601012) announced on the evening of March 13 that the company, the people’s Government of Inner Mongolia Eerduosi Resources Co.Ltd(600295) city and the people’s Government of Yijinholo banner signed the investment cooperation agreement on March 12, 2022, regarding the company’s investment and construction of 20GW monocrystalline silicon rod and chip project in mengsu economic Development Zone of Yijinholo banner, Inner Mongolia Eerduosi Resources Co.Ltd(600295) City, Inner Mongolia Autonomous Region 30GW high-efficiency single crystal cell project and 5GW high-efficiency photovoltaic module project reached a cooperation intention. The estimated investment amount of the project with an annual output of 20GW single crystal silicon rod and chip is 7.6 billion yuan, the estimated investment amount of the project with an annual output of 30GW high-efficiency single crystal cell is 10.3 billion yuan, and the estimated investment amount of the project with an annual output of 5GW high-efficiency photovoltaic module is 1.6 billion yuan.
Nanjing Vazyme Biotech Co.Ltd(688105) : Nanjing Vazyme Biotech Co.Ltd(688105) medically produced new coronavirus antigen detection kit completes the content change of the manual
Nanjing Vazyme Biotech Co.Ltd(688105) announced on the evening of March 13 that the wholly-owned subsidiary Nanjing Vazyme Biotech Co.Ltd(688105) medical obtained the medical device registration change document (in vitro diagnostic reagent) approved by the State Drug Administration on March 12, 2022 The New Coronavirus antigen detection kit produced by Nanjing Vazyme Biotech Co.Ltd(688105) has completed the intended use of medical device product registration, increased the sample type and the changes in the content of the instructions.
Pku Healthcare Corp.Ltd(000788) : the company has no plan to cooperate with foreign manufacturers
Pku Healthcare Corp.Ltd(000788) 3 on the evening of March 13, it was announced that the stock trading fluctuated abnormally. The company is concerned about recent media reports on the progress of oral drugs for covid-19 virus developed by yanyeyi pharmaceutical company in Japan. At present, the company has no plan to cooperate with foreign manufacturers. The company is now in the transitional period of restructuring of Founder group. For the company’s main business and core products, please refer to the annual report disclosed by the company.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) : the company’s covid-19 antigen detection reagent has submitted a registration application to the State Food and Drug Administration
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) 3 announced on the evening of March 13 that stock trading fluctuated abnormally. In March 11th, according to the National Health Protection Committee, after studying, the State Council responded to the joint prevention and control mechanism of New Coronavirus pneumonia, and decided to add antigen detection on the basis of nucleic acid detection, and formulated the “COVID-19 virus antigen detection application plan”. Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) said that covid-19 nucleic acid detection reagent company mentioned in the plan had been approved in March 2020 and continued to bring sales revenue to the company; Covid-19 antigen detection reagent of the company has submitted an application for registration to the State Drug Administration, and the acquisition time of the registration certificate is still uncertain.
Bgi Genomics Co.Ltd(300676) : change of medical device registration certificate of covid-19 antigen detection products of holding subsidiary
Bgi Genomics Co.Ltd(300676) 3 on the evening of March 13, it was announced that Huada, a holding subsidiary, changed the medical device registration certificate of covid-19 antigen testing products due to its recent acquisition of the medical device registration change document of the people’s Republic of China (in vitro diagnostic reagent) issued by the State Food and drug administration. The change of the registration certificate of medical devices for covid-19 antigen detection products of Huada Yinyuan mainly refers to the change of the expected use, instructions, storage conditions and validity period of the products in accordance with the application scheme for covid-19 virus antigen detection (Trial) and other relevant national regulations.
Guangzhou Wondfo Biotech Co.Ltd(300482) : approval certificate of New Coronavirus antigen test kit changed
Guangzhou Wondfo Biotech Co.Ltd(300482) 3 announced on the evening of March 13 that it had recently received a medical device registration change document issued by the State Drug Administration. Product Name: New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method); After change: [intended use] this product is used to qualitatively detect the new coronavirus n antigen in oropharyngeal swab, nasopharyngeal swab and nasal swab samples in vitro, and the sampling method of nasal swab samples is increased.
Beijing Oriental Yuhong Waterproof Technology Co.Ltd(002271) : increase the price of some main products of the company
Beijing Oriental Yuhong Waterproof Technology Co.Ltd(002271) 3 announced on the evening of March 13 that based on the continuous rise in the prices of main raw materials, resulting in the continuous increase of product costs, and combined with market demand and other factors, the prices of some main products of the company will be adjusted from March 16, 2022. The expected adjustment ranges are as follows: 1. Asphalt coiled material will be increased by 15% – 20%; 2. Polymer coiled material increased by about 10%; 3. Polyurethane coating increased by about 20%; 4. Water based coatings up by about 20%; 5. The increase of asphalt coating is about 20%.
[performance]
3Peak Incorporated(688536) : net profit of 443 million yuan in 2021, with a year-on-year increase of 141.32%
3Peak Incorporated(688536) 3 on the evening of March 13, the annual report was disclosed, and the operating revenue in 2021 was 1.326 billion yuan, a year-on-year increase of 134.06%; The net profit was 443 million yuan, a year-on-year increase of 141.32%; The basic earnings per share is 5.54 yuan. The company plans to distribute a cash dividend of 6.14 yuan (including tax) for every 10 shares.
Meihua Holdings Group Co.Ltd(600873) : net profit in 2021 increased by 139% year on year
Meihua Holdings Group Co.Ltd(600873) 3 on the evening of March 13, the annual report was disclosed. In 2021, the operating revenue was 22.837 billion yuan, an increase of 33.94% year-on-year, and the net profit attributable to the owner of the parent company was 2.351 billion yuan, an increase of 139.40% year-on-year; It is proposed to distribute cash dividend of 4.0 yuan (including tax) to all shareholders for every 10 shares.
Jiangsu Yitong High-Tech Co.Ltd(300211) : the net profit in 2021 was 28.46 million yuan, with a year-on-year increase of 208%
3 Hunan Tianrun Digital Entertainment & Cultural Media Co.Ltd(002113) disclose the annual report on the evening of March 13. In 2021, the operating revenue was 250 million yuan, with a year-on-year increase of 206.83%; The net profit was 28.46 million yuan, a year-on-year increase of 208.36%.
The basic earnings per share is 0.0940 yuan. It is proposed to distribute a cash dividend of 0.14 yuan (including tax) to all shareholders for every 10 shares.
Asymchem Laboratories (Tianjin) Co.Ltd(002821) : the operating revenue in the first quarter is expected to increase by more than 150% year-on-year
Asymchem Laboratories (Tianjin) Co.Ltd(002821) 3 announced on the evening of March 13 that the company has maintained a strong growth momentum this year. While continuing to undertake large orders, the business of other sectors showed a momentum of accelerated growth. The scale of orders on hand and the growth of revenue from January to February reached a record high. According to the preliminary accounting of the company, the operating revenue from January to February increased by more than 130% year-on-year. The company expects that the operating revenue in the first quarter of 2022 will increase by more than 150% year-on-year, with an amount of more than 2 billion yuan.
Baolingbao Biology Co.Ltd(002286) : the net profit from January to February was about 26 million yuan, reversing the loss year-on-year
Baolingbao Biology Co.Ltd(002286) 3 announced on the evening of March 13 that the company had a good start in production and operation from January to February and achieved good business results. According to the preliminary accounting of the company, from January to February 2022, the company achieved an operating revenue of about 401 million yuan, an increase of about 20.89% over the same period last year; The net profit attributable to the shareholders of the listed company was about 26 million yuan, with a loss of 4.1686 million yuan in the same period last year.
Jiangsu Eastern Shenghong Co.Ltd(000301) : net profit in 2021 increased by 490% year on year
Jiangsu Eastern Shenghong Co.Ltd(000301) 3 on the evening of March 13, the performance express was released. In 2021, the total operating revenue was 51.6 billion yuan, a year-on-year increase of 53.24%; The net profit was 4.523 billion yuan, a year-on-year increase of 490.01%.
Changsha Dialine New Material Sci.&Tech.Co.Ltd(300700) : the net profit from January to February was about 6.5 million yuan, with a year-on-year increase of about 220%
Changsha Dialine New Material Sci.&Tech.Co.Ltd(300700) 3 announced on the evening of March 13 that from January to February, the company’s main business showed a good growth trend. According to the company’s preliminary accounting, from January to February 2022, the company realized an operating revenue of about 72 million yuan, a year-on-year increase of about 155%, and a net profit attributable to shareholders of listed companies of about 6.5 million yuan, a year-on-year increase of about 220%.
Hainan Haide Capital Management Co.Ltd(000567) : the net profit from January to February was about 60 million yuan, with a year-on-year increase of about 240%
Hainan Haide Capital Management Co.Ltd(000567) 3 announced on the evening of March 13 that from January to February, the operating performance of the company increased steadily and the development momentum was good. After preliminary accounting, the company achieved a total operating revenue of about 104 million yuan, a year-on-year increase of about 113%; The net profit attributable to the shareholders of the listed company was about 60 million yuan, with a year-on-year increase of about 240%.
[increase / decrease]
New East New Materials Co.Ltd(603110) : the shareholders intend to reduce their shares by no more than 3%
on the evening of March 13, it was announced that the shareholder Huzhou guozan planned to reduce its holdings of no more than Ktk Group Co.Ltd(603680) 0 shares by means of centralized bidding and block trading, accounting for about 3% of the total share capital of the company. The reduction through centralized bidding will be carried out within 180 days after 15 trading days from the date of announcement of the reduction plan.
[Contract winning]
Guizhou Yibai Pharmaceutical Co.Ltd(600594) : participate in the centralized procurement of diclofenac and other drugs of Guangdong alliance, and it is proposed to be selected
Guizhou Yibai Pharmaceutical Co.Ltd(600594) 3 announced on the evening of March 13 that recently, the company’s subsidiary Chang’an pharmaceutical participated in the bidding for centralized procurement of diclofenac and other drugs by Guangdong alliance. Lobaplatin for injection of Chang’an pharmaceutical products is planned to be selected for this centralized procurement. Specification of the product to be selected: 10mg (calculated by anhydrous matter), price of the product to be selected: 3591928 yuan; The proposed winning price of lobaplatin for injection of Chang’an pharmaceutical products is 18% lower than the original benchmark price. If the company signs and implements the subsequent purchase and sales agreement, it will help to further expand the sales scope of the winning products and improve the market share of the winning products.
Xizi Jieneng: sign the contract for green fused salt energy storage demonstration project
Xizi Jieneng announced on the evening of March 13 that on March 12, the company signed the contract for green electric molten salt energy storage demonstration project with Shaoxing green electric energy Co., Ltd. The contract amount is 191 million yuan. The project is the demonstration application of molten salt energy storage technology independently developed by the company for many years. It will be the first green Zero Carbon Industrial Park project built by the company after Xizi aviation zero carbon smart energy plant.
Sundy Land Investment Co.Ltd(600077) : signing a cooperation agreement to provide financial assistance to foreign countries
Sundy Land Investment Co.Ltd(600077) 3 announced on the evening of March 13 that Songdu lithium Co., Ltd. and Qidi Qingyuan, the holding subsidiaries of the company, signed a consortium agreement to form a consortium to jointly participate in the implementation of Tibet Summit Resources Co.Ltd(600338) the equipment, operation and technical services of the 50000 ton lithium carbonate salt lake lithium extraction construction project of Argentina lithium potassium Co., Ltd Tibet Summit Resources Co.Ltd(600338) and the consortium signed the cooperation agreement on equipment, operation and technical services of the 50000 ton lithium carbonate salt lake lithium extraction construction project of Argentina lithium potassium Co., Ltd. Under the relevant contracts, the amount of equipment procurement involved is 1.6 billion yuan. Songdu lithium branch advances all contract equipment funds, that is, the amount of external financial assistance is 1.6 billion yuan. Songdu lithium has the right to charge interest at the annual interest rate of 8% according to the amount advanced. At the same time, during the cooperative operation period, Tibet Summit Resources Co.Ltd(600338) shall calculate the product processing fee and operation reward every month according to the agreement and pay it to the consortium.
[Others]
Jiangsu Hengrui Medicine Co.Ltd(600276) : it is proposed to repurchase shares with RMB 600 million-1.2 billion
6 Shenzhen Huijie Group Co.Ltd(002763) announced on the evening of March 13 that it is planned to repurchase shares at a price of 600 million yuan to 1.2 billion yuan, the repurchase price is no more than 60.22 yuan / share, and the source of share repurchase funds is the company’s own funds; The company’s shares are repurchased from the secondary market by means of centralized bidding transaction.
Hunan Warrant Pharmaceutical Co.Ltd(688799) : the drug has passed the evaluation of the consistency of quality and efficacy of generic drugs
Hunan Warrant Pharmaceutical Co.Ltd(688799) 3 announced on the evening of March 13 that recently, the company received the notice of approval for supplementary drug application for mycophenolate mofetil capsules approved and issued by the State Drug Administration. The drug mycophenolate mofetil capsule was evaluated by the consistency of quality and efficacy of generic drugs. The application of mycophenolate mofetil capsule together with corticosteroids, cyclosporine or tacrolimus is suitable for the treatment of patients receiving allogeneic kidney transplantation and liver transplantation, the prevention of organ rejection, and the induction and maintenance treatment of patients with type III-V adult lupus nephritis.
Some of the company’s control measures may be delayed in the first quarter
Jilin University Zhengyuan Information Technologies Co.Ltd(003029) 3 on the evening of March 13, it was announced that the company and its wholly-owned subsidiary information security company actively responded to the government’s epidemic prevention policy and would carry out relevant work mainly through online office and supplemented by closed office, so as to ensure the orderly operation of the company and information security company. As an information technology service enterprise, the company mainly provides products and services to customers according to their needs in daily operation. The epidemic control measures in Changchun may delay the execution of some orders in the first quarter of 2022. For projects delayed due to the epidemic, the company will actively and properly implement them in the follow-up period to ensure the smooth implementation of the project. It is expected that the epidemic will be effectively controlled with the joint efforts of the government and all sectors of society. At the same time, the headquarters of the company are located in Changchun and Beijing, and the business operations are located in many places across the country. Therefore, the impact of the epidemic on the business of the company is limited.
